

Sell-side analysts and investors visit Hikma Casablanca site

London, 14 November 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is today hosting sell-side analysts and investors at its offices and manufacturing facility in Casablanca, Morocco.

The visit will provide the opportunity for attendees to tour our facility, including our new sterile injectables plant, which is nearing completion. Senior members of the Middle East and North Africa (MENA) team will also present on our Branded and MENA Injectables businesses, our strategy and how we are uniquely placed to continue to deliver profitable growth in the region. No new material information will be provided.

The presentation is available on Hikma's website at <https://www.hikma.com/investors/results-and-presentations/>. A recording and transcript of the presentation and Q&A will be made available following the event.

-- ENDS --

Enquiries:

Hikma (Investors)

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050
Guy Featherstone Director, Investor Relations	+44 (0)20 3892 4389/ +44 7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 7970 709912

Teneo (Press)

Rob Yates	+44 (0)7715 375443
-----------	--------------------

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com